Antelope Sharp Pharmaceutical executives answer media reporter asked

Dispatch and Henan News (Xu Yu/Wen Wanglei/map) Recently, by the Henan Securities Regulatory Bureau guidance, Henan listed companies organized by the Association of Henan listed companies good faith convention Sunshine walk into the Antelope Rui Pharmaceutical (600285, shares bar) activities in Henan Antelope Sharp Pharmaceutical Co., Ltd. held.　　Henan listed Companies association representatives, institutional and personal investors representatives, brokerage analyst, some listed companies representatives, the news media and more than 40 people participated in the event.　　In the on-site face-to-face communication and communication links, the media representatives actively asked questions, antelope Sharp pharmaceutical executives to the confusion of the detailed answer.　　Media: Last year, Ling Ling Pharmaceutical Directional Additional, for oral drug base extension project, is the progress of fund-raising projects, what time to put into production? Antelope Sharp: Because of the Antelope Rui Pharmaceutical Xinyang Branch of the oral drug performance growth year after year, and the growing variety, the urgent need to launch new production lines to meet market demand. In 2011, the company launched the first refinancing since the listing, to the Xinyang branch of the oral drug Base Extension Project Project plan financing 386 million. Later, due to the shortage of two private equity funds, the company in January 2013 actually to three specific investors non-public offering shares, the net amount of money raised 208 million yuan. At the same time we carried out the adjustment of the project in time, in the premise of ensuring the reasonable use of funds, do not delay the normal operation of the project.　　From the current point of view, we through the effective management of funds to make the project progress is very smooth, production equipment and plant facilities, GMP certification, science and Technology park overall relocation of the three large chunks of project management in accordance with the planned advance, the relocation has entered the countdown phase, will be in the first half of next year Media: The pharmaceutical industry is known as the "eternal Chaoyang Industry", in the next few years, China's population aging, the National Health awareness, macro-economic development, health care expenditure gradually increased, medical preservation coverage, standardization of industry rules and other factors to promote the development of the pharmaceutical industry, in such a large environment,　　What is the company's future development strategy? Antelope Sharp: In the next few years, China's aging population intensified, health awareness significantly increased, the consumer structure of the escalating, the government to improve national health to the national strategy, the development of health industry has provided unprecedented support.　　The arrival of "aging age", gradually promote the health-represented service consumption continued to expand, the Chinese medicine derivatives industry has gradually matured, the relevant enterprises will share the Chinese population aging brought about by huge dividends.　　In this context, the company intends to do a good job on the basis of the pharmaceutical industry, based on local resources, around the "big health industry" positive layout, involved in health care and health industry, to build a large health industry chain. As the Chinese patent Medicine enterprise, the Antelope Sharp pharmacy enters "The big healthy" the industry to have the natural superiority. First of all, traditional Chinese medicine enterprises have brand advantages, brand effect has been deeply rooted. Pharmaceutical production of High-tech, strict management, the characteristics of the efficacy of traditional Chinese medicine enterprises to create a reliable image, so that the derivatives of traditional Chinese medicine enterprises more easily recognized by consumers. Second, the Chinese Medicine enterprises have research and development and quality advantages. Traditional Chinese Medicine stresses "Food and drug homology ", in the perfect research and development system and quality control, traditional Chinese medicine enterprises from the Cross of medicine to foods there is almost no technical barriers, and can be extracted from the herb or animal parts of beneficial ingredients, amplification of traditional Chinese medicine derivatives in the daily chemical products, health products or other market development space.　　Media: What do companies do to take on social responsibility?　　Antelope Sharp: The company actively fulfills the social responsibility obligation, fully realizes the enterprise and the Society overall coordinated sustainable development.　　First of all, the company to Henan Antelope Rui Old needy Areas Aid foundation for the platform, and actively participate in social public welfare activities, active participation in afforestation, needy areas aid and other public welfare undertakings, the "golden Autumn to realize student" activities to help support life difficulties and patients with severe disease family.　　Second, the Antelope Sharp pharmacy make full use of existing venues, plant, comprehensive technical renovation, the use of clean technology, production efficiency, and environmentally friendly high value-added products, protect the environment and ensure safety.　　In addition, the company in accordance with the "Company Law" "Securities law" "Listed Companies Governance guidelines" and other laws and regulations, and constantly improve corporate governance, improve the internal control system, forming a shareholder meeting, Board of Supervisors and management as the main structure of the decision-making and management system, and effectively protect the interests of shareholders,　　At the same time, the company adhere to the "customer first" principle, to provide customers with quality products, strengthen communication and cooperation with suppliers, the implementation of mutual benefit and win, abide by commercial rules, compliance with the contract and keep promise.　　　 The company also strictly abide by the "labor Law" labour contract law, "Women's Rights and Interests Protection Act" and other relevant laws and regulations, respect and maintain the personal rights and interests of employees, pay attention to the health, safety and satisfaction of employees, pay attention to personnel training, realize the common growth of employees and enterprises, seriously protect the rights and interests of employees, and fulfill the responsibility of enterprises.　　Media: As a pharmaceutical enterprise, antelope Sharp in drug quality management, what specific measures? Antelope Sharp: Companies adhere to the "Quality first" principle, set up a relatively complete quality control system, from the selection of material suppliers, review, material arrival acceptance, inspection and warehousing, production process of materials, intermediate products and packaging products control, finished product inspection, warehousing, to the factory sales,　　To product sales and product quality information feedback, the company has established a management standards, and strict implementation. The company fully and strictly implement the new version of GMP standards, through risk analysis, risk control, production key points control and other comprehensive norms of the company's production process to ensure product quality.　　Through a number of GMP production technology reform, a comprehensive upgrade of the quality of production management level to ensure that the company's products safe and reliable, and effectively protect the rights and interests of consumers. Quality control measures of the effective implementation of the company to enhance the quality of products for the company to expand the market lay a good foundation, Ling Rui Pharmaceutical won the "2011 provincial governor of Henan Province Quality Award"; The State Administration of quality inspection and quarantine awarded the chairman of Chonwey Pharmaceutical Co., Ltd. 2009 ~2010 Year " National quality work Advanced individual "honorary title and Medal of Honor, the national quality work advance units and individual individuals, 2011, the company was awarded the "2010 Henan Province Quality Credit Industrial enterprise" by the Quality and Technical Supervision Bureau of Henan Province.　　Media: Warm the current market prospects, there is no such products in the market? Antelope Sharp: As the future development direction of the enterprise, "Big Health Industry" future development prospects are very good.　　In addition to pharmaceuticals, non-pharmaceutical health products, including warm-up, are an important area for our future involvement. Warm hot patches through the physical effect of fever, does not belong to the drug, our other products-"infantile antipyretic paste" is also a physical cooling, there are some other non-pharmaceutical products, we are very optimistic.　　The state has increased its support in this regard, and relevant functional departments have promulgated relevant supporting policies. In terms of warming up projects, there are already such products in the market. Imported from Japan, the warm treasure in the domestic market is better, we have seen this opportunity, so the study of such products. The company has established specialized agencies to improve product capacity, increase product market promotion.　　We develop products in the future will be better than the products in the market, and product types will be richer, more humane.　　Media: At present, the National health awareness is increasing, medical expenditure is also gradually improving, there are many favorable factors to promote the development of the pharmaceutical industry, in such a large environment, the company's future development strategy is what? Antelope Sharp: The future of the company's development strategy will also be modern Chinese medicine, especially to paste mainly, while extending to the oral drug market.　　At the same time, we have to enter the "Big health Industry", which is a big step in the company's macro. From the microscopic point of view, paste is our company's core industry, is the company's "eldest son", shouldering an important responsibility.　　Paste the future development of the core strategy is to enter the National Base medicine Catalogue of opportunities, the company's flagship products rapidly expand the scale, increase sales share, and further enhance the core of the plaster of leadership position. The company produces one kind of oral medicine product has entered the national base medicine, this is also the future makes the big mouth to take the medicine the core method.　　In addition, in the future health care adjustment, some of the company's exclusive products to enter the scope of health care will be very rapid development. At the same time, we have to carry out a relatively large leap-into the "big health industry." It turns out that the plaster has always been defined as a patent medicine, but the company defines it as a fast consumer product. In foreign countries, plaster can be traded as a commodity at retail outlets. The development of our company, including advertising and the promotion of the terminal to promote the way, in fact, is a kind of fast consumer products operating mode. At present, in addition to drugs, we also operate such as fever stickers and the future of the warm paste, mask and so on. This kind of FMCG will become the new engine for the future development of the company, especially the FMCG products related to it will be a very big bright spot for our future development.